Chest Wall TumorNCT07040527
Comparative Study on Medical Artificial Intelligence Algorithm Assisted and Conventional Imaging Examination Methods
An observational study of Chest Wall Tumor, run by Shanghai Jiao Tong University Affiliated Sixth People's Hospital.
Trial summary
Chest wall tumors are one of the important diseases in thoracic surgery, and surgery remains the main method for treating this disease in clinical practice. The surgery for chest wall tumors requires extensive resection, and more importantly, precise resection. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Chest Wall Tumor
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 Jul 2025to 31 Dec 2028
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with benign or malignant chest wall tumors require surgical treatment ,meanwhile they have good overall condition and no signs of metastasis,
Who may be able to join
- 18-70 years old, male or female not limited Anesthesia ASA score I-II Malignant tumor of soft tissue in the chest Malignant tumors of ribs, rib cartilage, and sternum Tumors with uncertain or unknown properties of ribs, rib cartilage, and sternum Giant benign tumors of ribs, rib cartilage, and sternum The preoperative examination results indicate that the tumor has not undergone distant metastasis Willing to participate in the research and sign the informed consent form
Who cannot join
- Patients with distant metastasis detected during preoperative examination Inoperable tumor During the examination, it was discovered that the patient had another type of malignant tumor present ECOG 4 Suffering from active or chronic fungal/bacterial/viral infections History of allergy to anesthesia related drugs Heart and lung dysfunction, liver and kidney dysfunction, inability to tolerate surgery Patients with mental disorders who are unable to cooperate with treatment
About this study
Official title: Comparative Study on the Clinical Efficacy of Medical Artificial Intelligence Algorithm Assisted and Conventional Imaging Examination Methods for Chest Wall Tumor Surgery
Chest wall tumors are one of the important diseases in thoracic surgery, and surgery remains the main method for treating this disease in clinical practice. The surgery for chest wall tumors requires extensive resection, and more importantly, precise resection. If the resection range is insufficient, it is easy to cause tumor recurrence and metastasis, which affects the patient's survival; If the resection range is too large, it will cause damage to the chest wall structure, affecting the patient's postoperative recovery and quality of life. At present, the determination of the surgical resection range mainly relies on the experience of the surgeon and the results of imaging examinations. Even if experienced surgeons still have multiple imaging examination results, there are still clinical difficulties of insufficient or excessive resection. Medical artificial intelligence is the in-depth application of artificial intelligence technology in the field of medicine. By processing and analyzing massive amounts of medical data, it can accurately locate tumors and optimize surgical plans. Therefore, it is proposed to compare the clinical effects of surgical resection of chest wall tumors using medical artificial intelligence algorithms and conventional imaging examination methods, in order to understand whether it can achieve more accurate tumor resection.
Read the detailed description
Chest wall tumor is one of the important diseases in thoracic surgery, which can be classified as benign or malignant according to the nature of the tumor. At present, surgery is still the main treatment for this disease, even for a few malignant tumors that are sensitive to radiotherapy and chemotherapy, further surgical treatment is still needed after initial internal medicine treatment. Due to the different nature and location of tumors, the scope of surgical resection may vary greatly. Clinical studies have found that surgery for chest wall tumors requires the adoption of appropriate treatment plans based on the pathological results of the tumor, the location of tumor growth, the degree of local invasion of the tumor, and the presence of metastasis at the time of tumor detection. Further research has found that surgical resection of primary chest wall malignant tumors should be performed under careful planning, as most patients only have one chance of cure, and reoperation after tumor recurrence or surgical failure becomes very difficult. Moreover, even if these patients undergo reoperation, their prognosis is poor.
Malignant chest wall tumors require extensive resection to ensure the thoroughness of the surgery. However, the extensive chest wall defect formed after extensive resection can lead to the destruction of the integrity and stability of the chest wall. If not handled properly, it can cause chest wall softening, abnormal breathing, and acute respiratory failure in the early postoperative period, affecting the therapeutic effect of the surgery; However, in the late stage after surgery, chest wall deformities, pulmonary hernias, chronic respiratory dysfunction, and even scoliosis may occur, which can affect the quality of life.
Therefore, for chest wall tumor surgery, it is not only required to achieve thorough enlargement and resection, but also to consider precise resection to preserve the normal structure of the chest wall as much as possible to avoid adverse consequences. For some well-defined malignant tumors of the chest wall, determining the surgical resection margin is relatively simple. However, for other malignant tumors of the chest wall, such as those with invasive growth, those that recur after the first surgery, or those that recur locally after radiotherapy and chemotherapy, it is often difficult to determine the appropriate surgical resection range and resection margin in clinical practice. At this point, the surgical plan can only be determined and formulated based on the clinical experience of the surgeon and traditional imaging examination results before surgery, which has great uncertainty and increases the complexity and difficulty of the surgery.
Medical artificial intelligence is the in-depth application of artificial intelligence technology in the field of medicine. It integrates knowledge from multiple disciplines such as computer science, data science, and biomedical engineering, aiming to improve the efficiency, accuracy, and personalization of medical services by simulating human intelligent behavior. MedAI provides intelligent services for physicians to assist in diagnosis [5-7], recommend treatment methods, and monitor patients by processing and analyzing massive amounts of medical data, thereby optimizing the allocation of medical resources and improving the patient's medical experience.
At present, MedAI is mainly focused on screening lung nodules, determining the nature of lung nodules, and providing three-dimensional simulation imaging of lung nodules as a reference for surgical methods in the field of thoracic surgery. However, there have been no reports on its application in the clinical treatment of chest wall tumors. Therefore, we plan to conduct research in this area to broaden the application of MedAI in general thoracic surgery and provide better medical quality services for chest wall tumor patients, especially those with malignant chest wall tumors.
In the field of surgical planning for chest wall tumors, conventional imaging methods such as CT and MRI can provide basic anatomical information, but they have limitations. Doctors need to manually analyze two-dimensional images, which makes it difficult to accurately construct the three-dimensional spatial relationship between tumors and complex chest wall structures (such as ribs, blood vessels, and nerves), especially when the tumor boundaries are blurred and adhered to surrounding tissues, which can easily lead to surgical planning deviations and affect the integrity and safety of tumor resection The significant advantages of medical artificial intelligence algorithms in this regard lie in precise tumor localization, multidimensional data analysis, and surgical plan optimization.
- Conditions
- Chest Wall Tumor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Medical Artificial Intelligence Algorithm Assistance Group | Before surgery, medical artificial intelligence algorithms are used to outline the resection range of chest wall tumors, while during the actual surgical process, the resection range is determined by intraoperative frozen pathology. Ultimately, the value of medical artificial intelligence algorithm assistance will be evaluated based on paraffin pathology of surgical margins. | |
| Routine imaging examination group | Before surgery, conventional imaging methods are used to outline the resection range of chest wall tumors, while during the actual surgical process, the resection range is determined by intraoperative frozen pathology. The value of routine imaging examination was ultimately evaluated by paraffin pathology of the surgical margin. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pathological results of surgical margins for chest wall tumors
Pathological diagnosis of residual tissue cells after tumor resection
Measured: 3 years
Secondary outcomes (4)
Surgical margins planned by medical artificial intelligence
Surgical resection edges and ranges delineated with the assistance of medical artificial intelligence algorithms
Measured: 3 years
Surgical margins planned using conventional imaging techniques
The surgical resection edge and range delineated by conventional imaging examination methods
Measured: 3 years
recurrence-free survival, RFS
The time from surgery to the earliest evidence of recurrence
Measured: 3 years
Disease-free survival,DFS
The time at which the patient dies due to disease recurrence or progression after surgery
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jun 2025
- Study start1 Jul 2025 (estimated)
- Primary completion30 Jul 2025 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chest Wall TumorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Shanghai Jiao Tong University Affiliated Sixth People's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Wu Weiming, Shanghai Jiao Tong University Affiliated Sixth People's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07040527
- Sponsor's protocol ID
- 20250521
- Status last verified
- Jun 2025
- First submitted
- 19 Jun 2025
- Last updated
- 27 Jun 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Study on the Clinical Efficacy of Medical Artificial Intelligence Algorithm Assisted and Conventional Imaging Examination Methods for Chest Wall Tumor Surgery
- ClinicalTrials.gov ID
- NCT07040527
- Acronym / sponsor ID
- 20250521
- Conditions
- Chest Wall Tumor
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Shanghai Jiao Tong University Affiliated Sixth People's HospitalUniversity, hospital or other
- Study start
- 1 Jul 2025 (estimated)
- Primary completion
- 30 Jul 2025 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 27 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chest wall tumors are one of the important diseases in thoracic surgery, and surgery remains the main method for treating this disease in clinical practice. The surgery for chest wall tumors requires extensive resection, and more importantly, precise resection. If the resection range is insufficient, it is easy to cause tumor recurrence and metastasis, which affects the patient's survival; If the resection range is too large, it will cause damage to the chest wall structure, affecting the patient's postoperative recovery and quality of life. At present, the determination of the surgical resection range mainly relies on the experience of the surgeon and the results of imaging examinations. Even if experienced surgeons still have multiple imaging examination results, there are still clinical difficulties of insufficient or excessive resection. Medical artificial intelligence is the in-depth application of artificial intelligence technology in the field of medicine. By processing and analyzing massive amounts of medical data, it can accurately locate tumors and optimize surgical plans. Therefore, it is proposed to compare the clinical effects of surgical resection of chest wall tumors using medical artificial intelligence algorithms and conventional imaging examination methods, in order to understand whether it can achieve more accurate tumor resection.
Detailed description
Chest wall tumor is one of the important diseases in thoracic surgery, which can be classified as benign or malignant according to the nature of the tumor. At present, surgery is still the main treatment for this disease, even for a few malignant tumors that are sensitive to radiotherapy and chemotherapy, further surgical treatment is still needed after initial internal medicine treatment. Due to the different nature and location of tumors, the scope of surgical resection may vary greatly. Clinical studies have found that surgery for chest wall tumors requires the adoption of appropriate treatment plans based on the pathological results of the tumor, the location of tumor growth, the degree of local invasion of the tumor, and the presence of metastasis at the time of tumor detection. Further research has found that surgical resection of primary chest wall malignant tumors should be performed under careful planning, as most patients only have one chance of cure, and reoperation after tumor recurrence or surgical failure becomes very difficult. Moreover, even if these patients undergo reoperation, their prognosis is poor.
Malignant chest wall tumors require extensive resection to ensure the thoroughness of the surgery. However, the extensive chest wall defect formed after extensive resection can lead to the destruction of the integrity and stability of the chest wall. If not handled properly, it can cause chest wall softening, abnormal breathing, and acute respiratory failure in the early postoperative period, affecting the therapeutic effect of the surgery; However, in the late stage after surgery, chest wall deformities, pulmonary hernias, chronic respiratory dysfunction, and even scoliosis may occur, which can affect the quality of life.
Therefore, for chest wall tumor surgery, it is not only required to achieve thorough enlargement and resection, but also to consider precise resection to preserve the normal structure of the chest wall as much as possible to avoid adverse consequences. For some well-defined malignant tumors of the chest wall, determining the surgical resection margin is relatively simple. However, for other malignant tumors of the chest wall, such as those with invasive growth, those that recur after the first surgery, or those that recur locally after radiotherapy and chemotherapy, it is often difficult to determine the appropriate surgical resection range and resection margin in clinical practice. At this point, the surgical plan can only be determined and formulated based on the clinical experience of the surgeon and traditional imaging examination results before surgery, which has great uncertainty and increases the complexity and difficulty of the surgery.
Medical artificial intelligence is the in-depth application of artificial intelligence technology in the field of medicine. It integrates knowledge from multiple disciplines such as computer science, data science, and biomedical engineering, aiming to improve the efficiency, accuracy, and personalization of medical services by simulating human intelligent behavior. MedAI provides intelligent services for physicians to assist in diagnosis [5-7], recommend treatment methods, and monitor patients by processing and analyzing massive amounts of medical data, thereby optimizing the allocation of medical resources and improving the patient's medical experience.
At present, MedAI is mainly focused on screening lung nodules, determining the nature of lung nodules, and providing three-dimensional simulation imaging of lung nodules as a reference for surgical methods in the field of thoracic surgery. However, there have been no reports on its application in the clinical treatment of chest wall tumors. Therefore, we plan to conduct research in this area to broaden the application of MedAI in general thoracic surgery and provide better medical quality services for chest wall tumor patients, especially those with malignant chest wall tumors.
In the field of surgical planning for chest wall tumors, conventional imaging methods such as CT and MRI can provide basic anatomical information, but they have limitations. Doctors need to manually analyze two-dimensional images, which makes it difficult to accurately construct the three-dimensional spatial relationship between tumors and complex chest wall structures (such as ribs, blood vessels, and nerves), especially when the tumor boundaries are blurred and adhered to surrounding tissues, which can easily lead to surgical planning deviations and affect the integrity and safety of tumor resection The significant advantages of medical artificial intelligence algorithms in this regard lie in precise tumor localization, multidimensional data analysis, and surgical plan optimization.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 3 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Medical Artificial Intelligence Algorithm Assistance Group | – | –Before surgery, medical artificial intelligence algorithms are used to outline the resection range of chest wall tumors, while during the actual surgical process, the resection range is determined by intraoperative frozen pathology. Ultimately, the value of medical artificial intelligence algorithm assistance will be evaluated based on paraffin pathology of surgical margins. |
| Routine imaging examination group | – | –Before surgery, conventional imaging methods are used to outline the resection range of chest wall tumors, while during the actual surgical process, the resection range is determined by intraoperative frozen pathology. The value of routine imaging examination was ultimately evaluated by paraffin pathology of the surgical margin. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with benign or malignant chest wall tumors require surgical treatment ,meanwhile they have good overall condition and no signs of metastasis,
Key inclusion criteria (1 listed)
- 18-70 years old, male or female not limited Anesthesia ASA score I-II Malignant tumor of soft tissue in the chest Malignant tumors of ribs, rib cartilage, and sternum Tumors with uncertain or unknown properties of ribs, rib cartilage, and sternum Giant benign tumors of ribs, rib cartilage, and sternum The preoperative examination results indicate that the tumor has not undergone distant metastasis Willing to participate in the research and sign the informed consent form
Key exclusion criteria (1 listed)
- Patients with distant metastasis detected during preoperative examination Inoperable tumor During the examination, it was discovered that the patient had another type of malignant tumor present ECOG 4 Suffering from active or chronic fungal/bacterial/viral infections History of allergy to anesthesia related drugs Heart and lung dysfunction, liver and kidney dysfunction, inability to tolerate surgery Patients with mental disorders who are unable to cooperate with treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Pathological results of surgical margins for chest wall tumors
Time frame: 3 years
Pathological diagnosis of residual tissue cells after tumor resection
4 secondary outcomes
Surgical margins planned by medical artificial intelligence
Time frame: 3 years
Surgical margins planned using conventional imaging techniques
Time frame: 3 years
recurrence-free survival, RFS
Time frame: 3 years
Disease-free survival,DFS
Time frame: 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Chest Wall Tumor
RecruitingEarly Phase 1
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
Metastatic Triple-Negative Breast Carcinoma, Breast Cancer
RecruitingPhase 2
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
RecruitingPhase 2
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Amyloidosis, Basal Cell Carcinoma
Active, not recruitingPhase 2
Proton Radiation for Stage II/III Breast Cancer
Breast Cancer, Breast Neoplasm
RecruitingPhase 2
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
Chest Wall Tumor, Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Chest Wall Tumor, run by Shanghai Jiao Tong University Affiliated Sixth People's Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pathological results of surgical margins for chest wall tumors (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2025.